Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses
Authors:
- Nutan MytleNMNutan Mytle
- Sonja LeyrerSLSonja Leyrer
- Jon R. InglefieldJIJon R. Inglefield
- Andrea M. HarrisAHAndrea M. Harris
- Thomas E. HickeyTHThomas E. Hickey
- Jacob MinangJMJacob Minang
- Hang LuHLHang Lu
- Zhidong MaZMZhidong Ma
- Hanné AndersenHAHanné Andersen
- Nathan D. GrubaughNGNathan D. Grubaugh
- Tina GuinaTGTina Guina
- Mario H. SkiadopoulosMSMario H. Skiadopoulos
Open Access
Abstract
Influenza hemagglutinin (HA) is considered a major protective antigen of seasonal influenza vaccine but antigenic drift of HA necessitates annual immunizations using new circulating HA versions. Low variation found within conserved non-HA influenza virus (INFV) antigens may maintain protection with less frequent immunizations. Conserved antigens of influenza A virus (INFV A) that can generate cross protection against multiple INFV strains were evaluated in BALB/c mice using modified Vaccinia virus Ankara (MVA)-vectored vaccines that expressed INFV A antigens hemagglutinin (HA), matrix protein 1 (M1), nucleoprotein (NP), matrix protein 2 (M2), repeats of the external portion of M2 (M2e) or as tandem repeats (METR), and M2e with transmembrane region and cytoplasmic loop (M2eTML). Protection by combinations of non-HA antigens was equivalent to that of subtype-matched HA. Combinations of NP and forms of M2e generated serum antibody responses and protected mice against lethal INFV A challenge using PR8, pandemic H1N1 A/Mexico/4108/2009 (pH1N1) or H5N1 A/Vietnam/1203/2004 (H5N1) viruses, as demonstrated by reduced lung viral burden and protection against weight loss. The highest levels of protection were obtained with NP and M2e antigens delivered as MVA inserts, resulting in broadly protective immunity in mice and enhancement of previous natural immunity to INFV A.Keywords
This publication has 57 references indexed in Scilit:
- Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus InfectionPLOS ONE, 2013
- Single-Dose Vaccination of a Recombinant Parainfluenza Virus 5 Expressing NP from H5N1 Virus Provides Broad Immunity against Influenza A VirusesJournal of Virology, 2013
- Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1Scientific Reports, 2013
- Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscusPLOS ONE, 2013
- Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceVirology Journal, 2012
- A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 YearsPLOS ONE, 2012
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in HumansClinical Infectious Diseases, 2012
- Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individualsJournal of Clinical Investigation, 2008
- Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoproteinVaccine, 2007
- Poxvirus CD8+T-Cell Determinants and Cross-Reactivity in BALB/c MiceJournal of Virology, 2006